Skip to main content
Back
WGS logo

GeneDx Holdings Corp.

Data quality: 100%
WGS
NASDAQ Healthcare Medical - Healthcare Information Services
$66.95
▼ $1.72 (-2.50%)
Mkt Cap: 1.96B
Day Range
$66.87 $70.43
52-Week Range
$55.17 $170.87
Volume
435,481
50D / 200D Avg
$91.52 / $111.11
Prev Close
$68.67

Quick Summary

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (631 peers)

Metric Stock Sector Median
P/E -93.3 0.2
P/B 6.4 3.0
ROE % -7.6 3.6
Net Margin % -4.9 3.8
Rev Growth 5Y % 19.1 9.7
D/E 0.5 0.2

Analyst Price Target

Hold
$157.50 +135.3%
Low: $130.00 High: $170.00
Forward P/E
84.21
Forward EPS
$0.80
EPS Growth (est.)
+0.0%
Est. Revenue
550.26M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $8.76
$8.53 – $8.96
 1.38B 1
FY2029 $5.26
$5.13 – $5.38
 1.04B 1
FY2028 $3.05
$0.66 – $5.44
 844.59M 2

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-23 $0.10 $0.14 +36.9%
2025-10-28 $0.28 $0.49 +75.0%
2025-07-29 $0.10 $0.50 +400.0%
2025-04-30 $0.11 $0.28 +154.5%
2025-02-18 $0.04 $0.70 +1650.0%
2024-10-29 -$0.19 $0.04 +121.1%
2024-07-30 -$0.26 -$0.11 +57.7%
2024-04-29 -$0.68 -$0.33 +51.5%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Key Takeaways

Revenue grew 19.14% annually over 5 years — strong growth
Debt/Equity of 0.49 — conservative balance sheet
Generating 14.26M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 20.83%
Capital efficient — spends only 4.45% of revenue on capex

Growth

Revenue Growth (5Y)
19.14%
Revenue (1Y)39.97%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-7.60%
ROIC-1.92%
Net Margin-4.92%
Op. Margin-2.76%

Safety

Debt / Equity
0.49
Current Ratio2.46
Interest Coverage-4.65

Valuation

P/E Ratio
-93.28
Forward P/E84.21
P/B Ratio6.36
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 39.97% Revenue Growth (3Y) 45.28%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 19.14% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 427.54M Net Income (TTM) -21.02M
ROE -7.60% ROA -3.69%
Gross Margin 69.74% Operating Margin -2.76%
Net Margin -4.92% Free Cash Flow (TTM) 14.26M
ROIC -1.92% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.49 Current Ratio 2.46
Interest Coverage -4.65
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -93.28 Forward P/E 84.21
P/B Ratio 6.36 P/S Ratio 4.59
PEG Ratio 2.67 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 3.56 Fwd Earnings Yield 1.19%
FCF Yield 0.73%
Market Cap 1.96B Enterprise Value 2.01B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 427.54M 305.45M 202.57M 234.69M 212.20M
Net Income -21.02M -52.29M -175.77M -548.98M -245.39M
EPS (Diluted) -0.73 -1.94 -7.23 -53.63 -74.93
Gross Profit 298.17M 194.40M 90.01M -26.75M -16.60M
Operating Income -11.80M -23.21M -180.60M -667.65M -446.15M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 570.19M 419.38M 418.76M 545.26M 554.09M
Total Liabilities 262.01M 174.13M 190.74M 291.56M 165.99M
Shareholders' Equity 308.18M 245.25M 228.02M 253.71M 388.10M
Total Debt 151.95M 116.17M 119.77M 77.13M 32.85M
Cash & Equivalents 105.00M 85.21M 99.68M 137.40M 400.57M
Current Assets 268.29M 197.97M 182.34M 212.62M 483.54M
Current Liabilities 108.91M 54.82M 58.82M 144.30M 101.28M